Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs L 651582 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results comparing nocebo effects in older patients (n=446) enrolled in cancer therapeutic trials (NCCTG97-24-51 and ACOSOG Z9001), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 21 Dec 2010 Actual end date changed from Mar 2008 to Nov 2010 as reported by ClinicalTrials.gov.
    • 31 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top